SUMMARY A case of a 69 year old man in whom hypertrophic gastritis was associated with the carcinoid syndrome is reported. Concentrations of prostaglandin E2 were increased in plasma, gastric juice, gastric mucosa and urine. He had marked hypochlorhydria in response to pentagastrin stimulation (Peak acid output (PAO) pg:O02 mmol/h). After successful hepatic arterial embolisation of the metastases (as indicated by an 85% decrease in 24 h urinary 5-HIAA) the concentrations of prostaglandin E2 decreased in the plasma, gastric juice and gastric mucosa. The gastric mucosal hypertrophy regressed and secretion of acid in response to pentagastrin returned (PAO pg:9 ,0 mmol/h). These findings suggest that the carcinoid tumour was producing a substance which stimulated increased local synthesis of prostaglandin E2 in the gastric mucosa, with concomitant gastric mucosal hypertrophy and inhibition of gastric acid secretion.
Increased circulating concentrations ofprostaglandins (PGs) have been reported in patients with the carcinoid syndrome, and have been considered to contribute to the diarrhoea which occurs in that syndrome.'-3 It is uncertain whether the tumour itself produces these PGs or stimulates PG synthesis in other tissues by a humoral mediator. Oral and parenteral PGs cause hypertrophy of the gastric mucosa in rats45 and increased local PG synthesis has been postulated to be involved in the pathogenesis of hypertrophic gastritis in man. 6 We report a patient in whom the carcinoid syndrome was associated with hypertrophic gastritis and marked hypochlorhydria, and who had raised concentrations of prostaglandin E2 (PGE2) in the serum, gastric juice, gastric mucosa, and urine. After successful embolisation of the hepatic metastases the concentrations of PGE2 decreased to near normal concentrations, the gastric mucosal hypertrophy regressed, and gastric secretion in response to pentagastrin returned. 
Case history
The patient, a 62 year old man, presented in 1979 with dyspepsia. A barium meal showed giant gastric rugal folds and these appearances were confirmed at endoscopy. Biopsy showed the changes of chronic gastritis. At that time there was no diarrhoea, and other investigations were normal. The patient had a good symptomatic response to antacids. In 1985 he returned to the hospital with a history of diarrhoea for 18 months, and of excessive sweating and itching for 10 months. He had lost 3 kg in weight. On examination he had a cyanotic flush and there was nodular heptomegaly extending 10 cm below the costal margin.
The diagnosis of the carcinoid syndrome was made on the basis of raised 24 imaging showed that 70 to 80% of the liver was replaced with metastatic tumour.
A barium meal again showed gastric mucosal hypertrophy (Fig. la) . A small bowel series and barium enema failed to show a primary tumour. Endoscopy with four snare biopsies of the antral gastric mucosa showed striking foveolar hyperplasia with associated smooth muscle fibres evident in the lamina propria -recognised changes seen in hypertrophic gastropathies (Fig. 2a) . In addition there was evidence of severe active chronic gastritis with focal ulceration, luminal pus, and areas of intestinal metaplasia. Gastric secretory studies showed marked hypochlorhydria in response to pentagastrin stimulation (PAOpg;0.2/mmol/h). Basal serum gastrin measurements were within the normal range (0 to 100 ng/l) (Fig. 3) .
Serum alkaline phosphatase and y-glutamyl transpeptidase were raised at 344 U/l and 216 U/l respectively (normal ranges: 35-150 U/l and 5-50 U/l). Other investigations were either normal or negative, and included: full blood count, clotting profile, thyroid function tests, plasma cortisol, plasma catecholamines and urinary normetadrenaline excretion, meta-iodobenzoyl-glutamine scan, gastric parietal cell and intrinsic factor antibodies, Schilling test and 5'Cr-human serum albumin studies for increased protein loss from the gastrointestinal tract.
The patient received treatment with pizotifen 2 mg daily, codeine phosphate 120 mg daily, cyproheptidine 12 mg daily, and indomethacin 150 mg daily, without clinical benefit. A temporary therapeutic response was obtained during treatment with prednisolone 20 mg daily.
In March 1986 the patient was readmitted to hospital with worsening symptoms of diarrhoea, further weight loss of 4 kg, and peripheral oedema. Urinary 5-HIAA excretion had increased to 2673
[imol24 h (Fig. 3) . In view of the deterioration we undertook hepatic arterial embolisation using the Hammersmith Hospital protocol.7 Embolisation of the right hepatic artery was performed in March 1986, but for technical reasons it was not possible to embolise the left hepatic artery at the same time. Selective left hepatic arterial occlusion was performed in April 1986, when complete occlusion of the right hepatic artery was noted and a good therapeutic result was achieved as indicated by an 85% reduction in urinary 5-HIAA excretion (Fig. 3) .
After embolisation there was clinical improve- (Fig. 2b) . Further gastric secretory studies showed an increased gastric secretory response to pentagastrin with the PAOpg being 9*0 mmol/h and 7.0 mmol/h, four and seven weeks respectively after the second embolisation (Fig. 3) .
In an attempt to relate the gastric abnormalities to the carcinoid tumour, we measured prostaglandin E2 concentrations in plasma, gastric juice, urine, and gastric mucosa. Before embolisation of the hepatic metastases body fluid and tissue concentrations of PGE2 ranged from 2 to 140 times those measured in simultaneously studied controls (Table 1) . After embolisation concentrations were markedly reduced from pretreatment levels but remained raised compared with simultaneously studied controls. PROSTAGLANDIN 
ASSAYS
Prostaglandin concentrations in plasma, urine, gastric juice and gastric mucosal biopsies were measured on samples obtained in December 1985 (before hepatic arterial embolisation and before starting a therapeutic trial of indomethacin), and again after embolisation in May 1986 when indomethacin had been withdrawn for several weeks. Prostaglandin concentrations in plasma were measured after taking 10 On each occasion the average value from the two simultaneously studied control patients has been taken as 1-0 and the patient's results expressed as a multiple of this normalised value.
marked reduction in PGE2 concentrations after hepatic arterial embolisation indicates that the increased concentrations were dependent on the hepatic metastases. Carcinoid tumours secrete a wide variety of humoral substances,'7 some of which are candidate mediators of the increased synthesis of PGE2 observed in our patient. For example, serotonin has been shown to increase arachidonic acid metabolism in the gastrointestinal mucosa, and the secretory and motor effects of 5-HT have been considered to be mediated by PGE2.'819 When serotonin concentrations and PG concentrations were measured in the plasma of patients with the carcinoid syndrome although eight of 10 patients had increased serotonin concentrations, only one had increased concentra- 28 Achlorhydria has long been recognised as a feature of the carcinoid syndrome.29 Naturally occurring PGE2 and its synthetic analogues when administered either orally or parenterally inhibit gastric secretion in response to all stimuli, in healthy subjects and duodenal ulcer patients.3"32 In addition, PGE analogues inhibit the release of gastrin in response to food323334 and decrease the raised gastrin concentrations in patients who are achlorhydric in association with pernicious anaemia.33 As plasma gastrin concentrations increased in our patient after hepatic arterial embolisation, although gastric secretion of acid had also increased, it seems likely that the fasting gastrin concentrations were inappropriately low for the degree of hypochlorhydria, and that there was inhibition of gastrin release attributable to the increased local concentration of PGE2.
We have considered the possibility that other substances than PGE2 may have been responsible for the inhibition of gastric acid secretion and gastrin release in our patient. Serotonin and its precursor 5-hydroxytryptophan inhibit gastric secretion in dogs, but because the secretory inhibition observed is weak and poorly sustained,'343 and plasma concentrations of the inhibitory hormones somatostatin, secretin and VIP were within the normal ranges ( 
